Literature DB >> 20045645

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Christine E Brotherton-Pleiss1, Michael P Dillon, Anthony P D W Ford, Joel R Gever, David S Carter, Shelley K Gleason, Clara J Lin, Amy G Moore, Anthony W Thompson, Marzia Villa, Yansheng Zhai.   

Abstract

Despite the extensive literature describing the role of the ATP-gated P2X(3) receptors in a variety of physiological processes the potential of antagonists as therapeutic agents has been limited by the lack of drug-like selective molecules. In this paper we report the discovery and optimization of RO-85, a novel drug-like, potent and selective P2X(3) antagonist. High-throughput screening of the Roche compound collection identified a small hit series of heterocyclic amides from a large parallel synthesis library. Rapid optimization, facilitated by high-throughput synthesis, focusing on increasing potency and improving drug-likeness resulted in the discovery of RO-85. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045645     DOI: 10.1016/j.bmcl.2009.12.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Role of purinergic P2X receptors in the control of liver homeostasis.

Authors:  Michel Fausther; Emmanuel Gonzales; Jonathan A Dranoff
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

2.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 3.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 4.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

5.  Pyrid-2-yl and 2-CyanoPhenyl fused heterocyclic compounds as human P2X3 inhibitors: a combined approach based on homology modelling, docking and QSAR analysis.

Authors:  Sridhara Janardhan; Subhendu Seth; Vellarkad N Viswanadhan
Journal:  Mol Divers       Date:  2013-10-24       Impact factor: 2.943

6.  Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists.

Authors:  Diego Dal Ben; Michela Buccioni; Catia Lambertucci; Gabriella Marucci; Andrea Spinaci; Anna Marchenkova; Aliaa Abdelrahman; Andrea Nistri; Christa E Müller; Rosaria Volpini
Journal:  ACS Med Chem Lett       Date:  2018-12-26       Impact factor: 4.345

7.  Identification of a Unique Cytotoxic Thieno[2,3-c]Pyrazole Derivative with Potent and Selective Anticancer Effects In Vitro.

Authors:  Jessica D Hess; Luca H Macias; Denisse A Gutierrez; Karla Moran-Santibanez; Lisett Contreras; Stephanie Medina; Paulina J Villanueva; Robert A Kirken; Armando Varela-Ramirez; Manuel L Penichet; Renato J Aguilera
Journal:  Biology (Basel)       Date:  2022-06-18

8.  Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor.

Authors:  Claudio Coddou; Rodrigo Sandoval; María José Hevia; Stanko S Stojilkovic
Journal:  Neurosci Lett       Date:  2018-10-23       Impact factor: 3.046

9.  In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.

Authors:  Anthony P Ford
Journal:  Purinergic Signal       Date:  2011-11-18       Impact factor: 3.765

Review 10.  Heteromeric assembly of P2X subunits.

Authors:  Anika Saul; Ralf Hausmann; Achim Kless; Annette Nicke
Journal:  Front Cell Neurosci       Date:  2013-12-18       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.